Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Ahmet Aydin

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentUrology, College of Medicine
DivisionUrology Faculty
Address4301 W. Markham
Mail Slot # 540
Little Rock AR 72205
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Biben E, Menon L, Gokden N, Spond MF, Eichhorn JM, Aydin AM. Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report. BMC Urol. 2023 Dec 08; 23(1):204. PMID: 38066479.
      View in: PubMed
    2. Tu SM, Chen JZ, Singh SR, Aydin AM, Gokden N, Tam NNC, Leung YK, Langford T, Ho SM. Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care. Cancers (Basel). 2023 Nov 22; 15(23). PMID: 38067237.
      View in: PubMed
    3. Tu SM, Aydin AM, Maraboyina S, Chen Z, Singh S, Gokden N, Langford T. Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy. Cancers (Basel). 2023 Nov 13; 15(22). PMID: 38001645.
      View in: PubMed
    4. Goktas Aydin S, Kutlu Y, Muglu H, Aydin A, Acikgoz O, Hamdard J, Karci E, Bilici A, Olmez OF, Yildiz O. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemother Pharmacol. 2024 01; 93(1):71-78. PMID: 37773537.
      View in: PubMed
    5. Tu SM, Aydin AM, Maraboyina S, Chen Z, Singh S, Gokden N, Langford T. Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care. Cancers (Basel). 2023 Apr 27; 15(9). PMID: 37173982.
      View in: PubMed
    6. Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):453.e19-453.e26. PMID: 35811208.
      View in: PubMed
    7. Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 04; 40(4):164.e1-164.e7. PMID: 34629281.
      View in: PubMed
    8. Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mul? JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul 26; 13(15). PMID: 34359645.
      View in: PubMed
    9. Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mul? J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 05; 8(3):784-793. PMID: 33994165.
      View in: PubMed
    10. Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mul? J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021; 16(4):e0245415. PMID: 33882057.
      View in: PubMed
    11. Hajiran A, Azizi M, Aydin AM, Chakiryan NH, Peyton CC, Boulware DC, Manley BJ, Gilbert SM, Sexton WJ. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol. 2021 Jul; 28(7):3648-3655. PMID: 33689081.
      View in: PubMed
    12. Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021; 12:628063. PMID: 33717150.
      View in: PubMed
    13. Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May; 94:107481. PMID: 33636562.
      View in: PubMed
    14. Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mul? J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 04; 204(1):96-106. PMID: 33346915.
      View in: PubMed
    15. Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 12; 8(2). PMID: 33303579.
      View in: PubMed
    16. Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 01; 205(1):108. PMID: 33095102.
      View in: PubMed
    17. Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 01; 39(1):72.e1-72.e5. PMID: 33036902.
      View in: PubMed
    18. Aydin AM, Chakiryan NH, Spiess PE. Will Dynamic Sentinel Lymph Node Biopsy Become the New International Standard for Evaluating High-risk Penile Cancer in Patients with Clinically Negative Lymph Nodes? Eur Urol. 2020 12; 78(6):873-874. PMID: 33023773.
      View in: PubMed
    19. Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020 10; 17(10):555-570. PMID: 32812000.
      View in: PubMed
    20. Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan; 205(1):100-108. PMID: 32783489.
      View in: PubMed
    21. Chertack N, Ghandour RA, Singla N, Freifeld Y, Hutchinson RC, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Sagalowsky AI, Margulis V, Lotan Y, Woldu SL, Bagrodia A. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer. 2020 10 01; 126(19):4362-4370. PMID: 32776520.
      View in: PubMed
    22. Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 10; 27(10):882-889. PMID: 32767444.
      View in: PubMed
    23. Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Reply by Authors. J Urol. 2020 06; 203(6):1155. PMID: 32176595.
      View in: PubMed
    24. Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? J Urol. 2020 06; 203(6):1147-1155. PMID: 31928407.
      View in: PubMed
    25. Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020 Oct; 38(10):2537-2545. PMID: 31900581.
      View in: PubMed
    26. Aydin AM, Zemp L, Cheriyan SK, Sexton WJ, Johnstone PAS. Contemporary management of early stage testicular seminoma. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S36-S44. PMID: 32055484.
      View in: PubMed
    27. Cheriyan SK, Nicholson M, Aydin AM, Azizi M, Peyton CC, Sexton WJ, Gilbert SM. Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S45-S55. PMID: 32055485.
      View in: PubMed
    28. Azizi M, Aydin AM, Cheriyan SK, Peyton CC, Montanarella M, Gilbert SM, Sexton WJ. Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S91-S103. PMID: 32055490.
      View in: PubMed
    29. Aydin AM, Cheriyan S, Spiess PE. Treating advanced penile cancer: where do we stand in 2019? Curr Opin Support Palliat Care. 2019 09; 13(3):249-254. PMID: 31082941.
      View in: PubMed
    30. Hajiran A, Aydin AM, Cheriyan SK, Sexton WJ. A simplified new-generation renal mass complexity scoring system. Ann Transl Med. 2019 Sep; 7(Suppl 6):S223. PMID: 31656802.
      View in: PubMed
    31. Aydin AM, Pow-Sang JM. Editorial Comment. J Urol. 2019 06; 201(6):1125-1126. PMID: 30864907.
      View in: PubMed
    32. Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S. Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy. Ann Nucl Med. 2019 May; 33(5):326-332. PMID: 30778860.
      View in: PubMed
    33. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Nov; 37(11):2419-2427. PMID: 30759271.
      View in: PubMed
    34. Ceyhan E, Ileri F, Ceylan T, Aydin AM, Dogan HS, Tekgul S. Predictors of Recurrence and Complications in Pediatric Pyeloplasty. Urology. 2019 04; 126:187-191. PMID: 30682463.
      View in: PubMed
    35. Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. Eur Urol Oncol. 2018 08; 1(3):242-251. PMID: 31058267.
      View in: PubMed
    36. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul; 36(7):343.e1-343.e8. PMID: 29748098.
      View in: PubMed
    37. Tonyali S, Aydin AM. Evaluation of Deceased Kidney Donors for Renal Stone Disease: Is Computed Tomography Needed? Curr Urol. 2018 Mar; 11(3):113-116. PMID: 29692689.
      View in: PubMed
    38. Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia A. Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. Urology. 2018 02; 112:103-111. PMID: 29079210.
      View in: PubMed
    39. Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017 11; 17(11):1417-1431. PMID: 28832261.
      View in: PubMed
    40. Aydin AM, Katipoglu K, Baydar DE, Bilen CY. Long-standing aggressive angiomyxoma as a paratesticular mass: A case report and review of literature. SAGE Open Med Case Rep. 2017; 5:2050313X17712090. PMID: 28616233.
      View in: PubMed
    41. Aydin AM, Woldu SL, Hutchinson RC, Boegemann M, Bagrodia A, Lotan Y, Margulis V, Krabbe LM. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 2017; 10:1487-1502. PMID: 28331342.
      View in: PubMed
    42. Aydin AM, Eldem G, Peynircioglu B, Baydar DE, Bilen CY. Local recurrence of renal cell carcinoma that simulated multiple renal arteriovenous fistulas after laparoscopic partial nephrectomy: Report of a rare case. Int J Urol. 2016 10; 23(10):888-891. PMID: 27416885.
      View in: PubMed
    43. Aki FT, Aydin AM, Dogan HS, Donmez MI, Erkan I, Duzova A, Topaloglu R, Tekgul S. Does lower urinary tract status affect renal transplantation outcomes in children? Transplant Proc. 2015 May; 47(4):1114-6. PMID: 26036532.
      View in: PubMed
    Aydin's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (137) concept(s)
    _
    Co-Authors Expand Description
    See all (12) people
    _
    Similar People Expand Description
    See all (27) people
    _
    Same Department Expand Description
    Search Department